Trial Profile
A phase I/II trial of intravenous ranpirnase in subjects with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Ranpirnase (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2005 New trial record.